Abstract
Impulse control and related disorders (ICDs-RD) encompasses a heterogeneous group of disorders that involve pleasurable behaviors performed repetitively, excessively, and compulsively. The key common symptom in all these disorders is the failure to resist an impulse or temptation to control an act or specific behavior, which is ultimately harmful to oneself or others and interferes in major areas of life. The major symptoms of ICDs include pathological gambling (PG), hypersexualtiy (HS), compulsive buying/shopping (CB) and binge eating (BE) functioning. ICDs and ICDs-RD have been included in the behavioral spectrum of non-motor symptoms in Parkinson's disease (PD) leading, in some cases, to serious financial, legal and psychosocial devastating consequences. Herein we present the prevalence of ICDs, the risk factors, its pathophysiological mechanisms, the link with agonist dopaminergic therapies and therapeutic managements.
Definition
Impulse control and related disorders (ICDs-RD) encompass a heterogeneous group of disorders that involve pleasurable behaviors performed repetitively, excessively, and compulsively (–).
The common key symptom in all of these disorders is the failure to resist an impulse or temptation to control an act or specific behavior (, , ), which is ultimately harmful to oneself or others and interferes in major areas of life functioning (, , , , ).
The American Psychiatric Association's Diagnostic and Statistical Manual (DSM-5) included impulse control disorders (ICDs) in the chapter of “Disruptive, Impulse-Control, and Conduct Disorders” as a dysregulation of self-emotional and behavioral control ().
ICDs have recently been sub-classified as ICD groups and ICD-related disorder (ICDs-RD) groups (, , , ).
The major symptoms of ICDs include pathological gambling (PG), hypersexuality (HS), compulsive buying/shopping (CB) and binge eating (BE) (–, , , –).
However, PG was moved from the category of ICDs to a new category of “Substance-Related and Addictive Disorders” in the DSM-5 (–, , ), taking into account the similarities to drug addiction (risk factors, clinical features, cognitive changes, neurobiological substrates, and treatment approaches) (, ). This modification highlights the variability of reward-driven behaviors (, , , ).
The spectrum of ICDs-RD also includes punding, hobbyism, walkabout, hoarding, and compulsive medication use.
ICDs and ICDs-RD have been included in the behavioral spectrum of non-motor symptoms in Parkinson's disease (PD), leading in some cases to serious financial, legal and psychosocially devastating consequences with a greater impact on the quality of life. Moreover, in recent years we have noticed that PD patients are at increased risk of developing more than one of the major ICDs.
Along these lines, although it is not the focus of the present paper, some authors have suggested that the increased drive or motivation to certain behaviors cannot be harmful but rather beneficial (). Therefore, it remains under discussion whether artistic productivity or hypercreativity should be included in ICDs or in ICDs-RD, or if it might represent an innate–skill that emerges in PD patients on dopaminergic therapy (, , , , ).
Component Aspects
Three main aspects that characterize ICDs groups and ICD-related disorders in relation to reward-driven activities are:
The presence of impulsive aspects (lack of forethought or consideration of consequences) (, , ).
The presence of compulsive aspects (repetitive behaviors with a lack of self-control) (, , ).
A negative or harmful behavior to oneself or to others (, , ).
The four major ICDs include:
Pathological Gambling (PG) characterized by an excessive and uncontrollable “preoccupation with gambling and the excitement that gambling with increasing risk provides” despite financial loss and social problems (, , , –). PG was one of the earliest recognized ICDs in PD (). It was recently moved to the category of “Substance-related and addictive disorders” in the DMS-5, since substance abuse and PG activate brain reward areas and this bears similarities to drug addiction (, ).
Hypersexual disorder (HS) included in “The Sexual and Gender Identity Disorders Workgroup” of DSM-5 (). It could be described as an excessive amount of time consumed by sexual fantasies and by planning for engaging in sexual behavior which interferes with important activities and obligations in ordinary life (, ). Other behaviors that might often occur are fetishism and voyeurism (). As in substance abuse, patients with HS pursue a short-term reward and may develop tolerance and withdrawal-like syndromes (). This condition is more common among adult men, and it may additionally occur with erectile failure (, , , , ).
Binge eating has been included in “Feeding and Eating Disorders” in DSM-5 (, , ). It is “a persistent disturbance of eating or eating-related behavior that results in the altered consumption of food, which significantly impairs physical health or psychosocial functioning” (). The specific criteria proposed are:
Episodes of recurrent binge eating in the absence of any maladaptive compensatory behaviors.
Sense of lack of control over eating during the episodes.
Intake, in a discrete period of time (within any 2 h period), of an amount of food that is much larger than most people would eat in a similar period of time under normal circumstances.
The difference between binge eating and bulimia is that the former tends to be fluctuating while the latter is permanent (, ).
Compulsive buying (CB) is characterized by a constant urge to buy that leads to senseless contraction of debts with continuous delay of payment until a catastrophe clears the situation. As other ICDs, the repetitive loss of control over spending and the negative emotional state that emerges when not buying resemble substance use disorders (, ).
A prevalence of 5.8% in the general population at risk of CB is described (, ).
ICD-Related Behaviors (ICDs-RD)
ICDs-RD are classified as related behaviors that have a contrast clinical presentation with respect to the four major ICDs. However, the biological link between both conditions may be identified in the dysregulation or inappropriate regulation of the reward pathways in the mesocorticolimbic network (, ). ICDs-RD is characterized by repetitive perseverative behaviors that appear to be more closely linked to pulsatile drugs, such as levodopa or intermittent apomorphine therapy rather than dopaminergic agonist (DA) per se.
ICDs-RD include the following:
Dopamine dysregulation syndrome (DDS) is a drug addiction-like state characterized by a compulsive and excessive desire for use of high potency and short-acting dopaminergic medication (L-dopa, subcutaneous apomorphine) (–, –, , , , –, , ). DDS is more frequent in early-onset male PD patients with history of mood disorders and family history of psychiatric disorders (, ).
Punding is characterized by repetitive, purposeless behaviors and excessive preoccupation with specific items or activities, collecting, arranging or taking objects apart (–, –, , , –, , ). It has been reported to occur frequently in conjunction with DDS ().
Hobbyism pertains to higher-level repetitive behaviors (sports, artistic endeavors) (, , , , , , –).
Walkabout is excessive aimless wandering (, , , , , , , , –, ).
Hoarding is the acquisition of and failure to discard a large number of items with no objective value (–, , , ), (, , , ).
Epidemiology
ICD in the General Population
The prevalence of ICDs in the general population, which has been underestimated, shows a wide range with variability according to different populations: from 0.2 to 5.3% (). This enormous variability may be explained not only by different genetic, ethnic and cultural backgrounds, but also by the instruments used to assess these symptoms in the population (, –) (Table 1).
Table 1
| ICDs | General population | Dominion study ICD subgroup | ICARUS study (at baseline, use QUIP) ICD subgroup | The drug interaction with genes in Parkinson's disease DIGPD study (ICD at baseline) |
|---|---|---|---|---|
| Total | 0.2–5.3% | 17.10% | 28.6% | 19.7% |
| Age (mean SD) | N/A* | 60.2 (8.1) | 63.6 ± 9.5 | 58.5 (8.9) |
| UPDRS III score (mean SD) | N/A | 14.1 ± 5.89 | 18.8 (9.4) | |
| Cognitive scores MMSE adjusted total score | 27.9 ± 1.62 | 28.4 (1.7) | ||
| Disease Duration | 7.1 (3.8–10.8) | 6.9 ± 5.19 | 3.1 (1.4) | |
| Median dopamine agonist LEDD | 300 mg | N/A | 211.1 (118.0) | |
| Median levodopa LEDD associated DA | 450 mg | N/A | ||
| Median levodopa LEDD without a dopamine agonist | 621 mg | 263.4 (230.7) | ||
| Compulsive Buying | 5.8% (2–8) | 5.7% | 6.5% | 4.6% |
| Pathological Gambling | 0.4–1.1% | 5% | 5.30% | 3.9% |
| Binge eating | 2% | 4.3% | 9.9% | 10.5% |
| Hypersexual disorder | 3–6% | 3.5% | 9.7% | 8.5% |
| References | () | () | () | (33) |
Shows the estimated prevalence of each of the four major ICDs.
N/A
: non available or Non applicable.
Although the ICDs were initially reported in PD patients on DA therapies, some studies report the occurrence of ICDs in the general population and in novo PD patients (, , 34). It is still under discussion whether PD biology could be a risk factor for ICDs (35).
ICD in de novo PD
As mentioned above, it remains under discussion whether or not PD itself confers an increased risk for developing ICDs (35). Identifying the frequency of this disorder in novo PD patients could contribute to resolving these questions (). A recent study analyzing data from the Parkinson's Progression Markers Initiative failed to demonstrate an increased risk for the development of ICDs or ICDs-RB in PD patients in the absence of treatment. Nevertheless, some symptoms suggestive of ICD have been reported in 20% of newly diagnosed, untreated PD patients with respect to the appropriately matched controls (36). In recent years, imaging studies have offered relevant insight to this debate (35). However, at the moment, results remain controversial over whether PD itself constitutes a risk factor for the development of ICDS or ICDs-RD (, , ).
ICDs-RD in PD in Different Populations
ICDRs continue to be under-recognized and under-managed in clinical practice. Determining the true frequency of ICDs in the health population, in PD de novo patients, and in PD patients with and without DA agonist therapies in different populations represents a significant challenge since a number of variables must be analyzed, including assessment tools, DA dose, DA formulations, years of disease, as well as cultural and other factors. Moreover, in many cases more than one ICD has been identified (). In Table 2 we present a summary of various studies conducted to assess the presence of ICD behaviors over different periods of time and evaluate the risk factors and clinical characteristics.
Table 2
| References | Study | Type of study | Nparticipants | Scales | Age (mean/SD) years | Disease duration (mean/SD) years | Motor scores (mean/SD) | Levodopa or Levodopa equivalent LEED Dopamine agonist L-dopa dose equivalent DA-LEDD | Results | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name of the study | Geographic Distribution | PD | Controls | Motor | ICDs | Others | PD ICDs | PD non ICDs | PD ICDs | PD non ICDs | PD ICDs | PD non ICDs | |||||
| Driver- Dunckley et al. (37) | Initial | United States | Retrospective database | 1,884 | N/A | H&Y, UPDRS | N/A | 57.2 (30-72) | N/A | 11.6 (4–22) | N/A | mean H&Y stage 2.5 | N/A | Mean dose LEDD 883.4 mg/day | Pramipexole 4.3 mg/day Pergolide 4.5 mg/day | PG can occur as the PD progresses, appears with an increase in DA therapy and resolves reduction | |
| Maia et al. (38) | N/A | Brazil | Case/control study | 100 | 100 | UPDRS mHYS | Y-BOCS, | SEADLS | 62.2 ± 11.9 Total PD | N/A | N/A | Total UPDRS mean 40.28 ± 20.6 | N/A | OCD are NOT MORE frequent in PD patients | |||
| Weintraub et al. () | DOMINION Study | United States and Canada | Cross-sectional, multicenter | 3,090 | N/A | H&Y | Massachusetts Gambling Screen, MIDI | 60.2 (8.1) | 64.4 (7.8) | 7.1 (3.8–10.8) | 6.5 (3.7–10.6) | 2.0 (2.0–2.5) H&Y | 2.0 (2.0–2.5) H6Y | Pramipéxole 3.1 mg (SD, 1.7 mg) and LEDDs 306.9 mg (SD, 168.2 mg) Ropirinole 11.1 mg (SD, 6.6 mg) and LEDDs 277.9 mg (SD, 164.9 mg) Pergolide 2.9 mg (SD, 1.7 mg) and LEDDs 286.6 mg (SD, 169.3 mg) | DA treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD | ||
| Joutsa et al. (59) | Finland | Cross-sectional. | 575 | N/A | South Oaks Gambling Screen, QUIP, | BDI. | 64 (range 43–90) total PD | 6 (< 1–29) years Total PD | N/A | N/A | Total L-Dopa was 561 (26–3,230) mg DA LEDD was 160 (105–210) mg | There is a high proportion of patients with PD with ICDS. Prevalence of PG in PD is 7 times higher than general population. Depression associated with all ICDS. | |||||
| Sarathchandran et al. (39) | India | Case/control study | 305 | 234 | H&Y UPDRS | MIDI, DSM IV, BIS, BDI | Eysenck personality inventory; Anxiety and Depression Scale, PDQ-39 | 54.6 ± 9.9 | 59.6 ± 9.8 | 8.2 ± 4.9 | 7.3 ±4.8 | H&Y ON 2.0 ± 0.5 UPDRS-III ON 18.7 ± 9.2 | H&Y in ON 1.9 ± 0.5 UPDRS-III ON 18.5 ± 8.8 | PD without ICD LEDD: 448 ± 280 mg; L-Dopa:326.2 ± 31.9 mg PD with ICD LEDD: 590 ± 364.8 mg; L-Dopa: 373.4 ± 68.5 mg | Revealed a relatively higher frequency of ICD-RBs | ||
| Rodríguez-Violante et al. (40) | Mexico. | Case/control study | 300 | 150 | MDS-UPDRS H&Y | QUIP-RS | 58 ± 14.1 | 63 ± 12.5 | N/A | N/A | MDS- UPDRS part III 31 ± 15.9; H&Y: 2.2 ± 0.6 | MDS-UPDRS part III 32.8 ± 17; H&Y 2.3 ± 0.8 | PD with ICD group LEDD 638 ± 448.5 mg; DA-LEDD: 147.4 ± 123.3 mg PD without ICD LEDD: 561.3 ± 417.4 mg; DA-LEDD: 97.1 ± 124.9 mg | ICD significantly more frequent in PD than controls subjects. lower overall frequency and distinct pattern of ICDs related with socioeconomic differences | |||
| Ramírez Gómez et al. () | Argentina, Colombia, Ecuador | Multicenter. Structured Clinical Interview. cross-sectional | 255 | N/A | UPDRS; H&Y | QUIP, QUIP-RS; CISI-PD | 58.6 (SD, 11.11) | N/A | 4 | 10 | Mean UPDRS 10 | Mean UPDRS 33 | N/A | ICD in Latin American PD > Anglosaxon population | |||
| Rizos et al. (41) | UK, Spain, Denmark and Romania | Multicenter Retrospective and prospective survey based on medical records and clinical interviews. | 425 | N/A | H&Y | NMS Questionnaire | 62.7 (42–85) | 7.0 (0–24) | N/A | H&Y: 3.0 (1.0–5.0) | N/A | N/A | Relatively low rate of ICDs with long-acting or transdermal DAs. | ||||
| Vela et al. () | Spain | Multicenter study, Cross-sectional, case/control study | 87 | 87 | UPDRS; H&Y | QUIP | BID, EuroQol, PDQ-39 | 48 (44–52) | 46 (42–52) | 7 (3–11) | 3 (1–10) | Mean UPDRS III: 16 (10–22); H&Y:2 (2–2) | Mean UPDRS III 17 (11–24); H&Y 2 (1–2) | LEDD 300 (0–600) mg DA LEDD 210 (99–300) mg | ICBs are much more prevalent in early onset PD patients vs. health controls Associated with DA intake, depression and a worse QoL | ||
| Erga et al. () | Norwegian ParkWest Study | Norway | Multicenter Cross-sectional study, Semistructured Clinical interviews, cases and controls | 125 | 159 | UPDRS; H&Y | QUIP | MMSE, Stroop test, Semantic verbal fluency test, CLVT-II, VOSP, NPI, MADRS, Epworth Sleepiness Scale (PDSS-2 | 67.9 (7.7) | 71.4 (9.8) | 7.4 (1.6) | 7.4 (1.9) | H&Y: 2.2 (0.5); Mean UPDRS III: 23.8 (10.5) | UPDRS motor score 22.7 (10.6). H&Y: 2.2 (0.6) | PD without ICD LEDD: 408.7 ± 266.7 mg; DA LEDD:289.5 ± 150.0 PD with ICD LEDD: 505.2 ± 279.1; DA LEDD: 293.7 ± 132.4 | Patients with PD treated with DA, have increased odds of having ICBs compared with age- and gender-matched controls. | |
| Biundo et al. (42) | ALTHEA study | Italy | Multicenter | 251 | N/A | H&Y, UPDRS; UDysRS | QUIP-RS; BDI | MoCA;BDI-II | ICD-RBs below cut-off 66.5 6 10.2 ICD-RBs above cut-off 63.5 6 9.9 | 67.2 ± 9.4 | ICD-RBs below cut-off 52.7 ± 61.1 (months); ICD-RBs above cut-off 148.0 ± 64.5 (months) | 140.2 ± 68.21 (months) | ICD-RBs below cut-off UPDRS III: 11.9 ± 7.1 ICD-RBs above cut-off UPDRS III: 12.2 ± 7.4 | UPDRS III: 11.8 (6.9) | No ICD-RBs LEDD 971.0 6 ± 401.1 mg; DA-LEDD 147.0 6 ± 162.7 mg ICD-RBs above cut-off LEDD 1,016.4 6 ± 418.3 mg; DA-LEDD 133.1 ± 129.0 mg | >50% of PD patients with dyskinesia have ICDs and RBDs. Severity is associated with Dopaminergic therapy total dose | |
| Zhang et al. () | China | Xin Hua Hospital | 142 | H&Y, UPDRS, the scale for freezing of gait | QUIP. | MMSE, NMS, RBDQ-HK, HAMA, HAMD, PDQ- 39 | 65.55 ± 7.43 | 69.67 ± 8.16 | 7.76 ± 5.90 | 5.22 ± 5.23 | Mean UPDRS: 20.18 ± 11.56; H&Y: 2.32 ± 0.99 | Mean UPDRS: 18.93 ± 12.82; H&Y: 2.21 ± 0.77 | Total LEDD, mg PD without ICD:329.82 ± 340.65 mg PD with ICD: 522.06 ± 412.46 mg | ICD and RBD commonly found in Chinese PD patients. Independent factors associated with ICRDs: Earlier onset, dose of DA, severe cognitive impairment; dyskinesia. | |||
| Antonini et al. () | ICARUS Study | Italy | Prospective, non-interventional, multicenter | 1,069 DA alone L-Dopa alone L-Dopa + DA | H&Y, UPDRS | mMIDI; QUIP | NMSS, PDSS-2, PD-CRS, PDQ-8, BDI-II, FAB and three items of NPI-3: delusions, hallucinations and apathy/ indifference. | 63.6 ± 9.5 | 66.6 ± 9.3 | 6.9 ± 5.19 | 5.8 ± 4.92 | H&Y: 2.0 ± 0.70; Mean UPDRS III: 14.1 ± 5.89 | H&Y:2.0 ± 0.63; Mean UPDRS III: 14.2 ± 7.09 | N/A | Prevalence of ICD was relatively stable throughout the 2-years follow-up. No differences between patients receiving DAs and those on L-Dopa. No differences between PD with or without ICD in motor symptoms severity and cognitive function. | ||
| Corvol et al. (33) | DIGPD | France | Multicenter, face to face semistructured interviews. | 411 | N/A | MDS-UPDRS (parts I–IV) H&Y | MDS-UPDRS part I | Mini-Mental State | 58.5 (8.9) at Baseline | 63.3 (9.8) at Baseline | 3.1 (1.4) at Baseline | 2.5 (1.5) at Baseline | Mean UPDRS III: 18.8 (9.4) | Mean UPDRS III: 20.5 (10.5) | Baseline NO ICD LEDD 235.7 ± 181.1; DA-LEDD: 145.0 ± 99.1 ICD LEDD:263.4 ± 230.7; DA-LEDD: 211.1 ± 118.0 | 5-years cumulative incidence of ICDs ≈46%. ICDs: strongly associated with DA use and dose-effect. | |
Shows different epidemiologic studies.
Anxiety and Depression Scale; BDI-II, Beck Depressive Inventory; CISI-PD, Clinical Impression of Severity Index for Parkinson's Disease; CLVT-II, California Verbal Learning Test II; Epworth Sleepiness Scale; Eysenck personality inventory. FAB, Frontal Assessment Battery; H&Y, Hoehn & Yahr stage; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; MADRS, Montgomery and Asberg Depression Rating Scale; Massachusetts Gambling Screen; MDS-UPDRS; mH&Y, modified Hoehn & Yahr stage; mMIDI, modified versión of the Minnesota Impulsive Disorders Interview; MMSE, Mini Mental State Examination; MoCA, Montreal Cognitive Assessment; NMSS, Non-Motor Symptom Scale; NPI-3, Neuropsychiatric Inventory; PD-CRS, Parkinson's Disease-Cognition Rating Scale; PDQ-39, 39-item Parkinson's Disease Questionnaire; PDQ-8, Parkinson's Disease Questionnaire-8 items; PDSS-2, Parkinson's Disease Sleep Scale-2; QUIP, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease; QUIP-RS, Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale; RBDQ-HK, REM Sleep Behavior Disorder Questionnaire Hong Kong; SEADLS, Schwab and England Activities of Daily Living Scale; South Oaks Gambling Screen; UDysRS, Scale Unified Dyskinesia Rating Scale; UPDRS, Unified Parkinson's Disease Rating Scale; VOSP, Visual Object and Space Perception Battery; Y-BOCS, Yale Brown Obsessive Compulsive Scale; LEDD, L-dopa-equivalent daily dose; DAED, dopamine agonist-equivalent daily dose; DA, Dopamine Agonist; ICD, impulse control disorders; RBDs, Related Behavior Disorders.
Assessment Tools
Several instruments have been developed to assess and identify ICD symptoms in PD, some of which are summarized in Table 3.
Table 3
| Tools | Objectives | Brief description | Translated into other languages other than English | Self-administered | References | ||
|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | ||||
| Questionnaire for impulsive-compulsive disorders in PD (QUIP) | To screen ICRDs in PD patients. | Most commonly used, validated, self-report screening tool to assess ICDs | + German, Italian | + | (43) | ||
| QUIP rating scale (QUIP-RS) | To screen ICDs in PD patients | Rates severity of the ICDs and provides a measure of change over time | + German, Italian, Spanish | + | (44), (45, 46) | ||
| Minnesota Impulsive Disorders Interview (MIDI) | To assess the degree of impulsivity related to compulsive behavior | A questionnaire to assess the presence of impulsive–compulsive behaviors associated to dopamine replacement therapy in PD. | + | + | (47–49) | ||
| Dopamine Dysregulation Syndrome-Patient and Caregiver Inventory (DDS-PC) | To screen ICRDs in PD patients | Questionnaire to assess the presence of several ICD behaviors associated to DDS in PD, for both self-report and caregiver's report, to uncover eventual discrepancies. | + | + | (50) | ||
| Movement disorders Society UPDRS, included a single item for DDS | Not valid as an assessment tool for ICDs | The MDS-UPDRS contains questions/evaluations, divided in three domains scoring 18 items of motor, behavior and daily activities | + | + | (51) | ||
| Barrat Impulsiveness Scale (BIS) | To assess impulsivity in PD patients. | High reliability and high predictive validity to assess high risk behaviors including symptoms of conduct disorders, attention deficit disorders, substance abuse and suicide attempt. | + Brazilian Portuguese, Spanish, dialectal Arabic | + | (52–55) | ||
| Ardouin scale of behavior in Parkinson's disease | To assess neuropsychiatric features in PD patients | Specifically designed for asses mood and behavior, quantifying changes related to Parkinson's disease, to dopaminergic medication, and to non-motor fluctuations | + | + | (56) | ||
| Structured Clinical Interview for Obsessive-Compulsive Spectrum Disorders (SCID-OCSD) | To determine the presence of a range of ICDs. | A structured clinician-administered interview for the diagnosis of putative OCSDs | + | + | (57) | ||
| Parkinson's Impulse Control Scale (PICS) | To rate severity of ICD in PD patients. | A brief, clinician-rated screening tool that assess the intensity and impact of a wide range of ICBs common in PD | + | + | (58) | ||
Assessment tools.
QUIP, Questionnaire for impulsive-compulsive disorders in PD; QUIP-RS, QUIP rating scale; MIDI, Minnesota Impulsive Disorders Interview; DDS-PC, Dopamine Dysregulation Syndrome-Patient and Caregiver Inventory; BIS, Barrat Impulsiveness Scale; SCID-OCSD, Structured Clinical Interview for Obsessive-Compulsive Spectrum Disorders; PICS, Parkinson's Impulse Control Scale.
Risk Factors
Several studies have been conducted to identify the risk factors for ICD development in PD patients (). They include:
+ Demographic: young patient, male gender, unmarried (–, –, , , , 59, 60).
+ Treatment related: although ICDs have been reported to be associated to different drugs, such as L-dopa, amantadine and rasagiline, DA intake appears as the major risk factor for ICDs (–, , , –, –, , , 59, 60).
Prevalence of ICDs was compared among different DA drugs (pramipexole, ropirinole) and between extended releases or immediate formulations (, , , , 60). However, controversial findings from preliminary reports suggest that long-acting DA and patch or pump formulations may reduce the risk for ICDs (, , 61).
It remains under discussion whether there is an association between ICDs and DA dose. The same controversial results were reported regarding DA treatment duration, higher daily dose and DA higher peak dose (, , , 60).
+ Personal or family history: history of cigarette smoking, drug abuse, depression, apathy, REM behavior disorders (RBD), tea, coffee and mate consumption, positive personal or family history of alcoholism or gambling, and impulsive or novelty-seeking traits increase the risk for ICDs and their predictors (–, , –, , 59, 60).
+ PD onset and related ICDs: prevalence increases over time, while ICDs tend to occur in the first years of the disease. Early PD onset and the presence of motor complications of PD may predict a higher risk for ICDs (–, , , –, , , , 60).
+ Cultural factors: it remains to be determined if cultural factors may increase the risk for ICDs and ICRDs. Some authors suggest that cultural factors probably contribute not only to the prevalence of ICD but also the type of ICD (, ). One classic example in this field was provided by the DOMINIO study that suggests that living in the United States of America may be an independent risk factor for ICD development (, , ).
+ Deep Brain Stimulation (DBS): the relationship between ICDs and DBS remain under discussion. Initial studies reported improvement in ICDs after DBS, while subsequent studies showed ICD exacerbation (, , , 60, 62).
DBS of the subthalamic nucleus (STN) is an effective, widely used treatment for motor fluctuations or disabling dyskinesias in PD (63).
STN-DBS has been identified as an independent risk factor for ICRDs; however, the reduction of dopamine agonist dosage after STN-DBS could improve or decrease ICD occurrence (, , , 60, 62).
On the other hand, several studies suggest that DBS may contribute to impulsivity, excessive reward seeking and ICDs. Consistent with this hypothesis, PD patients without ICDs showed impulsive decision making when DBS is turned on (, 60, 62, 64).
To explain these controversial findings, it has been hypothesized that STN stimulation plays a role in dynamic aspects of impulse and inhibitory control (, 60).
+ Personality, Neuropsychiatric symptoms and Cognition in ICDs: a higher level of neuroticism, ineffective coping skills, and lower levels of agreeableness and conscientiousness in PD patients with ICDs has been reported (). Early onset PD patients constitute a high risk population for ICDs with a self-assertive/antisocial and reserved personality and somatization traits ().
A large constellation of comorbid affective symptoms and behavioral traits have been reported in PD with/or at risk for ICDs including depression, anxiety, novelty seeking, impulsivity symptoms and anhedonia (, 62, 65, 66). Interestingly, in PD patients with ICDs, apathy could be noticed during withdrawal from dopamine replacement therapy (DRT). Impulsivity and apathy are two major comorbid syndromes of PD that may represent two extremes of a dysexecutive and behavioral spectrum involving dopamine-dependent cortico-striato-thalamo-cortical networks (64).
+ Cognition: controversial data have been identified in cognitive battery tests between PD patients with and without ICD (, 36); the first group presents values lowered in some tests that evaluate the frontal lobe, but did not find significant differences in executive functioning (, 67). Cognitive flexibility and ability to plan is altered in patients with ICD ().
Visuo-spatial working memory and reward-punishment learning impairments have been reported in different studies; however, many results could not be replicated (, ).
Interestingly, patients with ICDs showed a more immediate reward response and greater choice impulsivity leading to increased risk behavior ().
When the cognitive performance was compared according to the type of ICD it was found that patients with HS showed greater general cognitive impairment, including lower performances on learning tests and were more impaired on the Stroop test and memory tasks than were patients with PG (, 68). However, another study found no differences in the executive functions of patients with PD and PG (69).
+ Genetics: genetic factors have been involved in ICDs in PD. Although heritability was estimated to be 57%, consensus remains a challenge and data need to be replicated in large cohorts from different populations (). A large number of single nucleotide polymorphisms (SNP) in dopaminergic, glutamatergic, serotonergic, and opioid neurotransmitter systems has been reported as a candidate that improved predictability of ICDs when compared with clinical risk factors (, , , , , 70). Recently, an association of OPRM1 rs1799971 was identified, a gene encoding the mu opioid receptor with ICDs. This gene is central to pain control as well as drug reward and addictive behaviors (70).
In Table 4 we present the genetic factors reported to be related to ICDs.
Table 4
| Receptor types | Genotype | Associations | References |
|---|---|---|---|
| Dopamine | DRD1rs4867798, rs4532, rs265981 | Increased risk of ICDs | (, 71, 72) |
| PD: punding and hobbyism behaviors, ICDs | |||
| Non-PD: ICDs, neuropsychiatric disease, problem gambling, addiction, and cognitive functioning in non-PD population | |||
| DRD2 Taq1A Dopamine transporter (DAT1) | No association | () | |
| DRD2/ANKK1 rs1800497 | Increased risk of ICDs | (, , 65, 71) | |
| Dopa decarboxylase (DDC) rs 3837091; rs 1451375 | Stronger predictor f ICDs | () | |
| D3Rp.S9G | ICDs and levodopa-induced dyskinesias | (, , , , , , 65, 73) | |
| Stronger predictor of ICDs | |||
| Glutamate | Grin2B rs7301328 | Increased risk of ICDs | (, , , , , 71) |
| Monoamine Transporters | COMT gene Val158 Met | No association | (, 65) |
| COMT rs4646318 | No association | () | |
| Opioid | OPRK1 rs702764 | Stronger predictor f ICDs | (, , 65, 72) |
| Serotonine | Hydroxytryptamine receptor HTR2A rs6313 | Stronger predictor f ICDs | (, , , , , ) |
We present the genetic factors reported to be related to ICDs.
Interestingly, the ICARUS study, the largest prospective observational study in an Italian population, contributes to the identification of additional risk factors that include non-motor symptoms (mood and sexual function), mood symptoms (depression), sleep disorders and a low level of quality of life ().
+Other Risk Factors
Recently, the overexpression of ΔFosB, a transcriptional regulator involved in addiction induced by drugs of abuse and in many types of compulsive behaviors has been reported to be associated with L-dopa induced dyskinesia and to be triggered by pramipexole (60).
The ΔFosB overexpression was identified in the nucleus accumbens (NA) and the striatum (brain regions important for addiction) of healthy and DA-lesioned rats exposed to pramipexole and found to be NMDA receptor dependent. These findings suggest that enhanced ΔFosB expression may represent the strongest predictor of PD patients at risk of ICDs (, 60).
Pathophysiology
Although an extensive number of studies have focused on the pathophysiologic mechanisms of ICDs in PD, these remain to be clarified (, ). Classically, the appearance of impulsivity in PD has been attributed to neuronal dopaminergic degeneration, facilitating ICD occurrence in dopamine replacement therapies ().
Nevertheless, in recent years, evidence has suggested a complex multifactorial mechanism beyond the dopaminergic corticostriatal networks, including a complex serotoninergic and noradrenergic interaction. Further investigation is required ().
Dopaminergic Theory
Dopaminergic receptors, Dopamine 1 receptor 1 (D1R) (D1 and D5) and Dopamine 2 receptor (D2R) (D2, D3, D4) types possess contrasting roles with inhibitory and excitatory signaling, respectively. These contrasting roles are present not only in the nigro-striatal pathway but also in the mesolimbic and mesocortical circuits. The pathways link cortical and subcortical regions [prefrontal cortex (PFC), ventral striatum, VTA and amygdala]; both circuits are implicated in reward learning and executive decision making or reinforcement behaviors, respectively (, , 74).
Anatomical regions involved in ICDs:
Planning and judgment areas: caudal orbitofrontal cortex, ventromedial prefrontal cortex (PFC).
Reward system: ventral striatum (VS-nucleus accumbens [NA]).
Conditioned responses and emotional processing: amygdala.
Medial dorsal and anterior nucleus of the thalamus (, 75).
In PD with ICDs a marked decrease ventrostriatal D3R-binding has been reported, while experimental PD models have shown an increase in DA levels in the NA associated to bilateral nigrostriatal DA denervation (64, 76). These findings, of a diminished striatal D2/D3 receptor level and an increase in mesolimbic DA tone, lead to an imbalance in the cortico-accumbens network implicated in reward signaling and behavioral changes (64, 77, 78). Moreover, the dopaminergic mesocorticolimbic system provides a role for shift behavior in response to changing stimulus-reward contingencies (64).
In this scenario, the tonic “overdosed” by D2/D3 receptor agonists in the mesocorticolimbic circuit could contribute to suppress, through the impairment of top-down inhibitory control from prefrontal cortical area (PFC) inputs to the ventral striatum, reward-related learning and induce compulsive, perseverative behavior through the direct D1 receptor pathway (, , ).
Dopaminergic agonists (DA) show a high D3R affinity in the mesolimbic system (, , , 60). In effect, DA therapy, acting on the depleted dorsal striatum (involved in the sensory-motor circuit) and a relatively intact ventral striatum, induces a reduction of inhibitory response and impulse control by the reduction of activity in the lateral orbitofrontal cortex, the rostral cingulated zone, the amygdala, and in the external pallidum (, ). Therefore, PD patients on DA are not only at high risk for ICDs but also demonstrate greater choice impulsivity, shorter reaction time and increased risk taking (, 79).
The D1 receptor family localize in the direct pathway of reward-based behaviors. Stimulation increases the activity of striatal projections to the nucleus accumbens/ventral striatum, while D2 receptors elicit suppression of the cortico-accumbens network (, , 80).
Neuroimaging in PD Patients With ICDs
In recent years neuroimaging, particularly that which is focused on the dopaminergic system, has significantly contributed to the knowledge of neurobiological factors for ICDs (, , , 81, 82) (see Tables 5A–D).
Table 5A
| Study objectives | Participants | Results | References | ||
|---|---|---|---|---|---|
| PD ICD/RBDs | PD No ICD/RBDs | Controls | |||
| To demonstrate morphometric changes | X | X | X | No significant changes PD + ICD vs. PD-ICD | (83) |
| To measure brain cortical thickness and subcortical volumes, and to assess their relationship with presence and severity of symptoms, in PD patients with and without ICDs. | x | x | x | In ICD+: Significant cortical thinning in right superior orbitofrontal, left rostral middle frontal, bilateral caudal middle frontal region, and corpus callosum and reduced volume in right accumbens and increase in left amygdala in ICD | (84) |
| To identify Neuroanatomical abnormalities in PD patients with PG | Pathological Gambling (PG) | X | X | Gray matter loss in bilateral Orbitofrontal-cortex in PD-PG vs. PD-CNTR correlated with increase of gambling symptoms in PD-PG | (85) |
| To assess brain structural and functional alterations in patients PD-ICB vs. controls and PD no-ICB | x | x | x | Cortical thinning in left pre-central and superior frontal cortices, as well as decreased FA of the left uncinate fasciculus and parahippocampal tract; increased mean, radial and axial diffusivity of the left parahippocampal tract and right pedunculopontine tract; increased mean and radial diffusivity of the genu of the cingulate cortex and right uncinate fasciculus. | (86) |
| To assess whether a functional dysregulation of the habenula and amygdala (modulators of the reward brain circuit), contributes to PD punding. | X Punding | x | x | Cortical thinning of right inferior frontal gyrus compared to controls and PD-without punding | (87) |
| To investigate structural abnormalities in mesocortical, limbic cortices and subcortical structures in PD ICDs. | x | x | x | Volume loss in the nucleus accumbens of PD patients. PD-ICD showed significant increased cortical thickness in rostral anterior cingulte cortex and frontal pole compared to PD-without ICD. Increased cortical thickness in medial prefrontal regions in PD-ICD | (88) |
| To determine morphometric changes as predictors of ICB in de novo PD | x | x | x | No significant morphometric changes in PD-ICD and PD-without ICD before and after onset of ICD. | (89) |
| To better understand the neural basis of ICDs in PD | x | x | x | PD-ICD patients showed a reduced gray mater volume in External Globus Pallidus compared to PD-without ICD | (90) |
| To investigate gray matter (GM) and cortical thickness (CTh) changes in PD with and without ICDs. | x | x | x | Increased cortical thickness in anterior cingulate cortex, orbitofrontal cortex in PD-ICD. | (91) |
| Morphometric Changes in PD punding patients | Punding | X | X | Significant cortical thinning in dorsolateral prefrontal cortex in PD-punding. Cortical thinning in PD-punders localized in prefrontal cortex extending into orbitofrontal cortex. | (92) |
Structural MRI.
Table 5B
| Study objectives | Participants | Results | References | ||
|---|---|---|---|---|---|
| PD ICD/RBDs | PD No ICD/RBDs | Controls | |||
| To assess brain white matter tract alterations in PD+ punding vs. controls and PD ICD, and PD non-ICD | PD + Punding | PD Punding – | X | Greater damage of genu of corpus callosum and left pedunculopontine tract in PD-punding vs. PD-without ICD | (93) |
| To assess brain structural and functional alterations in patients with PD-ICB vs. with controls and PD no-ICB cases. | x | x | x | Cortical thinning in left pre-central and superior frontal cortices, as well as decreased Fractional anisotropy (FA) of the left uncinate fasciculus and parahippocampal tract; increased mean, radial and axial diffusivity of the left parahippocampal tract and right pedunculopontine tract; increased mean and radial diffusivity of the genu of the cingulate cortex and right uncinate fasciculus. | (86) |
| To determine the changes in DTI associated with medication-related ICD in PD patients undergoing chronic dopamine-replacement therapy. | x | x | x | PD-ICD showed significantly elevated FA in anterior cingulate cortex (ACC), right internal capsule posterior limbs, right posterior cingulum, and right thalamic radiations compared to PD-without ICD | (92) |
| To identify alterations of white matter tract in drug-naïve PD- ICDs | x | x | x | Decreased connectivity in left and right cortico-thalamic tract, left and right cortico-pontine tract, left and right corticospinal tract, left and right superior cerebellar peduncle and left and right middle cerebellar peduncle between PD-ICD compared to PD-without ICD. Decreased connectivity in left and right inferior longitudinal fasciculus, genu and body of corpus callosum, left and right corticospinal tract, left superior cerebellar peduncle and left and right cingulum in PD-ICD compared to control. | (94) |
Diffusion-tensor images.
Table 5C
| Study rationale | Participants | Ligand | Results | References | ||
|---|---|---|---|---|---|---|
| PD ICD/RBDs | PD No ICD/RBDs | Controls | ||||
| RESTING-STATE fMRI | ||||||
| To identify corticostriatal connectivity (especially between ventral striatum and cortical limbic regions) in PD ICDs | X | X | X | Resting state | Significant functional disconnection between left anterior putamen and both left inferior temporal gyrus and left ACC, in PD-ICD | (95) |
| To investigate functional alterations in PD ICB+; vs. controls and PD no ICB | X | X | x | Increased functional connectivity of bilateral pre-central and post-central gyrus in PD-without ICDs vs. control and PD-ICD. Increased functional connectivity in left frontoparietal and visual network positively correlated with ICD duration | (86) | |
| To assess whether a functional dysregulation of the habenula and amygdala (modulators of the reward brain circuit), contributes to PD punding | Punding | X | x | Higher functional connectivity of habenula and amygdala with thalamus and striatum bilaterally, and lower connectivity between bilateral habenula and left frontal and pre-central cortices in PD-punding vs. PD-without ICDs and control. Lower functional connectivity between right amygdala and hippocampus in PD-punding vs. PD-without ICD. | (87) | |
| To investigate differences in both affective and sensorimotor striatal circuitries between PD ICD, PD-No ICDS and association with impulsive behavior | X | X | N/A | PD-ICD compared to PD-without ICD: Stronger connectivity between left putamen and central operculum, left caudate and occipital fusiform gyrus and various cerebellar regions, left Globus Pallidus internali and left superior temporal gyrus, left subthalamic nucleus(STN) and left caudate, parietal and temporal areas. Weaker connectivity between left GPe and various frontal cortical areas, left STN and various frontal areas, parietal area and paracingulate, middle frontal gyrus and subcortical areas. | (90) | |
| To investigate brain network connectivity at baseline in a cohort of drug-naive PD patients who successively developed ICDs over a 36-month follow-up period compared with patients who did not. | Drug Naive PD | X | Increased baseline connectivity in subtantia nigra (SN) and decreased baseline connectivity in default mode network and central executive network in PD patients who develop ICD after chronic dopaminergic treatment compared to those who did not | (96) | ||
| To investigate intrinsic neural networks connectivity changes in PD with and without ICD. | X | X | x | Increased connectivity in salience network and default mode network and decreased connectivity in central executive network in PD-ICD. Increased connectivity in salience network positively correlated with ICD symptom severity. | (97) | |
| TASK-BASED fMRI | ||||||
| To identify differences in CBF responses to DA in mesocorticolimbic regions in PD patients with and without ICD | X | X | N/A | On/Off state | Increased CBF in bilateral striatum, SN, periaqueductal gray matter, insular cortex, and ventromedial prefrontal cortex in PD-ICD compared to PD-without ICD. Increased CBF in bilateral VS in PD-ICD in ON state vs. OFF state. | (98) |
| To identify dysfunctional brain reward networks in PD- Dopamine dysregulation síndrome (DDS) | DDS | X | N/A | ON and OFF medication states. Drug-related visual stimuli. Drug Effects Questionnaire | Exposure to drug-cues increase subjective feeling of being “ON” during both “ON” and “OFF” medication scans, which corresponds to significantly increased activation in ventral striatum (VS) in PD-DDS. | (99) |
| To demonstrate that DA treated PD patients with ICDs have increased functional connectivity between the ventral striatum and components of the limbic striato-pallido-thalamocortical loop and additionally to explore amygdala connectivity with reward network components. | X | X | N/A | Incentive learning task with “gain” and “loss” conditions. ON and OFF medication states | Elevated ventral striatal connectivity to anterior cingulate cortex (ACC), orbitofrontal cortex (OFC), insula, putamen, globus pallidus and thalamus in PD-ICD patients compared to PD-without ICD. No difference in connectivity seen between ON and OFF medication scans. Ventral striatum to subgenual ACC connectivity positively correlated with reward learning performance. | (100) |
| To demonstrate a link between hypersexuality in PD and increased processing in brain regions linked to sexual motivation and cue reactivity | Hypersexuality (PD-HS) | X | N/A | Visual stimuli presented of sexual, other-reward related and neutral cues. ON and OFF medication states | Increased sexual desire correlated with enhanced activation in VS, cingulate and OFC in PD-HS when ON medication. | (101) |
| To quantify resting cerebral blood flow (CBF) and blood oxygenation level dependent (BOLD) fMRI to measure neural responses to risk taking during performance on the Balloon Analog Risk Task (BART). | X | X | N/A | Balloon Analog Risk Task | Significantly reduced BOLD activity in right ventral striatum during all risk taking trials and significantly reduced resting CBF in right ventral striatum, in PD-ICD | (102) |
| To demonstrate that DA would be associated with faster learning from gain outcomes along with greater ventral striatal positive δ activity in PD ICDs vs. PD without ICDs | X | X | X | Probabilistic reward learning task. ON and OFF medication states. | Greater left OFC activity in PD-DD patients compared to PD-without ICD. PD patients in the ON state compared to OFF state learn faster from gain outcomes during the task along with greater ventral striatal activity to unexpected rewards. | (103) |
| To demonstrate that DA would be associated with greater risk taking and lower ventral striatal activity in PD with ICD vs. PD without ICD | X | X | X | Risk task with “Gain” and “Loss” condition. ON and OFF medication states. | ON state associated with lower bilateral ventral striatal activity compared to the OFF state in patients with ICD with the reverse finding in PD control group. Greater correlation between BOLD activity and risk in PD-ICD compared to PD-without ICD in bilateral ACC and caudate, and left OFC. | (104) |
Resting state and Task-based fMRI.
Table 5D
| Study objectives | Participants | Ligand | Results | References | ||
|---|---|---|---|---|---|---|
| PD ICD/RBDs | PD No ICD/RBDs | Controls | ||||
| PET | ||||||
| To evaluate l-dopa induced dopamine neurotransmission in the striatum of patients with DDS compared with PD control patients. | Dopamine dysregulation syndrome (DDS) | x | N/A | [11C] raclopride (D2/D3-affinity) | Greater reduction in ventral striatal binding potential in DDS (14.4%) vs. control (3.6%). Positive correlation with L-DOPA wanting but not liking | (105) |
| To investigate the effects of reward-related cues and L-dopa challenge in patients with PD ICD; and PD without ICD on striatal levels of synaptic dopamine | x | x | N/A | Greater reduction in ventral striatal binding potential following task in ICD (16.3%) vs. control (5.8%). | (106) | |
| To compare dopaminergic function during gambling in PD patients, with and without pathological gambling (PG), following dopamine agonists. | PD-PG | x | N/A | Greater reduction in ventral striatal binding potential during task in ICD (13.9%) vs. PD control (8.1%) | (107) | |
| (1) To investigate dopamine neurotransmission in PD patients with multiple ICDs, single ICDs and non-ICD controls in response to reward-related visual cues. (2) To compare clinical features of the above three groups. | Single ICD Multiple ICDs | X | N/A | Greater reduction in ventral striatal binding potential in single (17.19%) and multiple ICD (17.51%) vs. control (6.47%). No significant difference between ICD groups | (108) | |
| To investigate whether ICD in PD are associated with greater D3 dopamine receptor availability | x | x | x | [11C]-(+)-PHNO (D3-affinity | Greater reduction (20%) in ventral striatal binding potential in ICD vs. non-ICD. | (109) |
| To investigate the role of extrastriatal dopaminergic abnormalities in PD patients with PG | Gambling (PD-PG) | X | N/A | [11C] FLB-457 (Extra- striatal D2/D3 affinity) | Greater reduction in midbrain binding potential in PG vs. control during gambling. Increase in binding potential in ACC in PG vs. control in control task | (110) |
| To investigate the possible involvement of the mesostriatal and mesolimbic monoaminergic function in ICDs associated with PD | x | X | N/A | [18F] F-Dopa | Increased binding potential (35%) in medial orbitofrontal cortex in ICD vs. control PD without ICD. | (111) |
| To investigate DA-induced changes in brain activity that may differentiate patients with PD with DA-induced PG) from PD without PG | PD-Gambling (PG) | X | H2(15)O [Regional cerebral blood flow (rCBF)] | Significant reduction in rCBF in left lateral orbitofrontal cortex, right rostral cingulate zone, right amygdala, left ventral anterior external pallidum in PG, while controls showed increased rCBF in these areas for ON vs. OFF phase scans. | (112) | |
| To investigate the extrastriatal dopaminergic neural changes in relation to the medication-related ICDs in PD. | X | x | x | [18F]FP-CIT (DAT density/PET) | Increased binding potential in right ventromedial prefrontal cortex, left insular and right posterior cingulate cortex and reduced binding potential at left nucleus accumbens, ventral striatum and ventral pallidum, in ICD vs. non-ICD. | (113) |
| To describe the metabolic PET substrate and related connectivity changes in PD ICDs. | X | X | N/A | [18F] FDG | Increased glucose metabolism in right middle and inferior temporal regions in PD-ICD compared with PD-CNTR. Higher metabolism in these areas in patients with multiple ICDs vs. single ICD | (114) |
| SPECT | ||||||
| To investigate resting state brain perfusion in PD patients with active PG compared with PD controls and healthy controls. | PG X | X | X | [123I]FP-CIT (DAT density/SPECT | Reduced DAT binding in right ventral striatum (nucleus accumbens) of PD-PG compared to PD-CNTR | (115) |
| To assess presynaptic dopaminergic function | X | X | x | Reduced tracer binding in the ventral striatum of PD patients with PG compared to PD controls | (116) | |
| To assess striatal dopamine transporter (DAT) density in PD ICD | X | X | N/A | Lower DAT binding in right striatum with trend in ICD. | (117) | |
| To follow-up data from medication-naïve PD patients who underwent dopamine transporter SPECT imaging at baseline and were subsequently treated with DA replacement therapy. | PD-Drug Naïve and subsequently treated with dopaminergic therapy | N/A | [123I]FP-CIT (DAT density/SPECT | 11 patients developed ICD symptoms after DRT. PD-ICD patients had lower DAT availability in right ventral striatum, anterior-dorsal striatum and posterior putamen compared to control | (118) | |
| To assess cortico-striatal connectivity in PD ICDs | X | X | N/A | Significant reduction in tracer uptake in left putaminal and left inferior frontal gyrus in PD-ICD vs. PD without ICDl. | (119) | |
| To investigate resting state brain perfusion in PD PG compared with matched PD controls and healthy controls. | X | X | X | 99mTc-ECD (rCBF/SPECT) | PD-PG showed a disconnection between the ACC and the striatum, which was not observed in PD patients without PG and HC groups. | (115) |
PET and SPECT Studies.
Structural and Functional Magnetic Resonance Imaging
Structural MRI changes have been reported in PD patients with ICDs with a selective atrophy in the orbitofrontal and anterior cingulate cortices (areas involved in behavioral modulation). Atrophy in the orbitofrontal cortex has been reported in PD patients with ICDs (85, 91).
Functional brain resonance (fMRI) studies have reported an abnormal metabolism on the frontostriatal and cingulate cortices, the nucleus accumbens and the amygdala (, 120).
A connectivity dysfunction between the striatal and limbic areas has been proposed. Brain connectivity was impaired in PD patients with ICDs with respect to the PD individuals without ICDs involving the neurocognitive network. A decreased connectivity has been identified in the central executive networks (mediofrontal areas, anterior cingulate and para-cingulate cortices), while an increased connectivity has been identified in the salience network (limbic-paralimbic network) and in the default mode network (pre-cuneus and posterior cingulate, bilateral inferior-lateral-parietal and ventromedial frontal cortices) (95, 97).
Single photon emission computed tomography (SPECT) of the dopamine transporter (DAT).
DAT regulates dopamine turnover. A reduced DAT binding in PD patients with PG and ICDs has been identified in PD patients with ICD compared to PD patients without ICD or healthy controls. This reduced binding of DAT has been suggested as a potential biomarker for risk of developing ICD symptoms (, 36, 60). The binding reduction was not uniformly reproduced in different studies: some reported a reduction in right ventral striatum (, 102), while others in the left putamen and left inferior frontal gyrus. These data could reflect a mesolimbic projection and frontostriatal disconnection, suggesting a vulnerability or maladaptive synaptic plasticity under non-physiological DA stimulation ().
Positron Emission Tomography (PET) With 11C-raclopride
Positron emission tomography (PET) neuroimaging with 11C-raclopride explores the DA fluxes within the basal ganglia. The 11C-raclopride is a reversible binding to the post-synaptic D2/3 receptor that competes with endogenous DA (, , , 106, 107). Decreased 11C-raclopride binding is an indirect measure of increased endogenous dopamine release or “hyperdopaminergic state.”
A significant reduction of 11C-raclopride binding has been reported in ventral striatum, but not in dorsal striatum, in PD with ICDs (single or multiple) as compared to PD individuals without ICDs, following generic reward-related vs. neutral visual stimuli.
A more selective radioligand [18F]fallypride, with high affinity D2-like receptors (D2/D3 receptors) confirmed a reduced binding within the VS and putamen (121).
All of these findings contribute to support a mesocorticolimbic imbalance in PD with ICDs (108).
PD- ICDs Treatment
The first approach for ICD is prevention, and a key element is patient and family education concerning potential risks of different dopaminergic therapies. Physicians should be aware of predisposing risk factors and balance cost/benefit before DA prescriptions, excluding genetic factors and taking into consideration clinical findings, such as young age, early PD onset, lengthy disease duration, personal history of addictive behaviors, male gender, short-acting DA drugs, behavior and mood disorders (apathy, depression), DBS and certain cultural factors that require attention before prescription.
When ICDs appear, treatment continues to be a challenge. Individualized treatment must be conducted, identifying potential variables, such as motor status, comorbidities, other non-motor symptoms and quality of life (, 122, 123).
The relevance of prevention is supported by NICE guidance that includes written information, or verbal information recorded in writing, at DA initiation of treatment. The authors emphasize the relevance of communicating to patients, relatives and carers the risk of ICDs due to the potential impact on their lives and for early detection (124).
The first approach for the treatment of ICD symptoms is the reduction or discontinuation of DAs. However, it should be considered that neuropsychiatric traits may persist for at least 12 weeks after drug withdrawal (60, 61, 123).
Nonetheless, in certain cases this strategy is not feasible, and some patients are at risk of developing DA withdrawal syndrome and worsening motor symptoms (, 61, 123).
Although animal PD models have identified serotonin (5HT) depletion as a higher risk for impulsivity and risk behaviors, the serotonin reuptake inhibitors (SSRIs) used to treat ICDs had controversial results (, 123).
Atypical antipsychotics, such as clozapine and quetiapine have been used to treat ICDs in PD, but no randomized trials have been conducted and evidence is limited (, ).
Taking into consideration that specific SNP opioid receptors have been identified as stronger risk factors for ICDs, opioid antagonists employed in the treatment of PG have produced controversial results (naltrexone, nalmefene) (, , , , 60, 123).
A number of drugs administered to increase Gabaergic inhibition (valproate, topiramate), as well as new drugs to preserve ventral striatal DA system (zonisamide, donepezil, noradrenaline reuptake inhibitor) have been essayed ().
As previously mentioned, controversial data are available concerning DBS and ICD treatment. A favorable response through reduction in dopaminergic requirements has been noted. It has been suggested that STN stimulation could reduce the risk for ICDs by increased reward-driven behaviors by inhibitor effect in the indirect dopaminergic pathway. However, some patients may develop transient de novo ICDs after STN DBS, and selective patients may develop ICDs a long time after DBS (123, 125).
A non-pharmacologic approach includes cognitive behavioral therapy and patient and caregiver education (, 60).
Conclusions
The treatment used for PD, particularly DA, is associated with the development of ICDs and related behaviors. Susceptibility to these disorders depends on the associated risk factors.
ICDs can have serious personal, family, psychosocial, financial, and medical consequences. However, in contrast, artistic activities have been described in patients with PD while undergoing treatment with DA. These patients are compulsive but report a positive influence on quality of life.
These findings highlight the need for a very critical approach at the moment of Dopaminergic Replacement therapy choice.
Statements
Author contributions
EG: study concept, design, and editing. VA: study concept and editing of manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
WeintraubDDavidASEvansAHGrantJEStacyM. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. (2015) 30:121–7. 10.1002/mds.26016
2.
Jiménez-UrbietaHGagoBde la RivaPDelgado-AlvaradoMMarinCRodriguez-OrozMC. Dyskinesias and impulse control disorders in Parkinson's disease: from pathogenesis to potential therapeutic approaches. Neurosci Biobehav Rev. (2015) 56:294–314. 10.1016/j.neubiorev.2015.07.010
3.
MaloneyEMDjamshidianAO'SullivanSS. Phenomenology and epidemiology of impulsive-compulsive behaviours in Parkinson's disease, atypical Parkinsonian disorders and non-Parkinsonian populations. J Neurol Sci. (2017) 374:47–52. 10.1016/j.jns.2016.12.058
4.
ZhangYHeALiLChenWLiuZ. Clinical characteristics of impulse control and related disorders in Chinese Parkinson's disease patients. BMC Neurol. (2017) 17:98. 10.1186/s12883-017-0874-6
5.
RamírezGómez CCDueñasMSBernalOAraozNSáenz FarretMAldinioVet al. A multicenter comparative study of impulse control disorder in Latin American patients with Parkinson disease. Clin Neuropharmacol. (2017) 40:51–5. 10.1097/WNF.0000000000000202
6.
WeintraubDO ClaassenD. Impulse control and related disorders in Parkinson's disease. Int Rev Neurobiol. (2017) 133:679–717. 10.1016/bs.irn.2017.04.006
7.
CossuGRinaldiRColosimoC. The rise and fall of impulse control behavior Disorders. Parkinsonism Relat Disord. (2018) 46Suppl. 1:S24–9. 10.1016/j.parkreldis.2017.07.030
8.
MarquesADurifFFernagutPO. Impulse control disorders in Parkinson's disease. J Neural Transm. (2018) 125:1299. 10.1007/s00702-018-1870-8
9.
BhattacharjeeS. Impulse control disorders in Parkinson's disease: pathophysiology, effect of genetic polymorphism and future research directions. Austin J Clin Neurol. (2017) 4:1100. 10.4103/0028-3886.237019
10.
MüllerAReinKKolleiIJacobiARotterASchützPet al. Impulse control disorders in psychiatric inpatients. Psychiatry Res. (2011) 188:434–8. 10.1016/j.psychres.2011.04.006
11.
TamamLBicanMKeskinN. Impulse control disorders in elderly patients. Compr Psychiatry. (2014) 55:1022–8. 10.1016/j.comppsych.2013.12.003
12.
JoutsaJMartikainenKKaasinenV. Parallel appearance of compulsive behaviors and artistic creativity in Parkinson's disease. Case Rep Neurol. (2012) 4:77–83. 10.1159/000338759
13.
López-PousaSLombardía-FernándezCGarre OlmoJMonserrat-VilaSVilalta-FranchJCalvó-PerxasL. Dopaminergic dysregulation, artistic expressiveness, and Parkinson's disease. Case Rep Neurol. (2012) 4:159–66. 10.1159/000343946
14.
BentivoglioARBaldoneroERicciardiLDe NigrisFDanieleA. Neuropsychological features of patients with Parkinson's disease and impulse control disorders. Neurol Sci. (2013) 34:1207–13. 10.1007/s10072-012-1224-5
15.
Garcia RuizPJMartinez CastrilloJCAlonso-CanovasAHerranz BarcenasAVelaLSanchez AlonsoPet al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. (2014) 85:841–5. 10.1136/jnnp-2013-306787
16.
KraemmerJSmithKWeintraubDGuillemotVNallsMACormier-DequaireFet al. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry. (2016) 87:1106–11. 10.1136/jnnp-2015-312848
17.
VelaLMartínez CastrilloJCGarcía RuizPGasca-SalasCMacíasMacías YPérez FernándezEet al. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: a cross-sectional multicenter study. J Neurol Sci. (2016) 368:150–4. 10.1016/j.jns.2016.07.003
18.
WangXPWeiMXiaoQ. A survey of impulse control disorders in Parkinson's disease patients in Shanghai area and literature review. Transl Neurodegen. (2016) 5:4. 10.1186/s40035-016-0051-7
19.
AntoniniABaronePBonuccelliUAnnoniKAsgharnejadMStanzioneP. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry. (2017) 88:317–24. 10.1136/jnnp-2016-315277
20.
ErgaAHAlvesGLarsencJPTysnesdOBPedersenaKF. Impulsive and compulsive behaviors in Parkinson's disease: the Norwegian ParkWest Study. J Parkinsons Dis. (2017) 7:183–91. 10.3233/JPD-160977
21.
VriendC. The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks. Cell Tissue Res. (2018) 373:327. 10.1007/s00441-017-2771-0
22.
LopezAMWeintraubDO ClaassenD. Impulse control disorders and related complications of Parkinson's disease therapy. Semin Neurol. (2017) 37:186–92. 10.1055/s-0037-1601887
23.
KulisevskyJPagonabarragaJMartinez-CorralM. Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity. J Neurol. (2009) 256:816–9. 10.1007/s00415-009-5001-1
24.
CanesiaMRusconibMLMoronibFRanghettibACeredacEPezzoliaG. Creative thinking, professional artists, and Parkinson's disease. J Parkinsons Dis. (2016) 6:239–46. 10.3233/JPD-150681
25.
World Health Organization. International Classification of Diseases (ICD-10): Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization (1992).
26.
GiovannoniGO'SullivanJDTurnerKMansonAJLeesAJL. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. (2000) 68:423–8. 10.1136/jnnp.68.4.423
27.
VargasAPCosta CardosoFE. Impulse control and related disorders in Parkinson's disease. Arq Neuropsiquiatr. (2018) 76:399–410. 10.1590/0004-282X20180052
28.
AngiolettiLSiriCMeucciNPezzoliGBalconiM. Pathological gambling in Parkinson's disease: autonomic measures and impaired decision-making. Eur J Neurosci. (2018). [Epub ahead of print]. 10.1111/ejn.13993
29.
WeintraubDKoesterJPotenzaMNSiderowfADStacyMVoonVet al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. (2010) 67:589–95. 10.1001/archneurol.2010.65
30.
WarrenNO'GormanCLehnASiskindD. Dopamine dysregulation syndrome in Parkinson's disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry. (2017) 0:1–5. 10.1136/jnnp-2017-315985
31.
PezzellaFRColosimoCVanacoreNDi RezzeSChianeseMFabbriniGet al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. (2005) 20:77–81. 10.1002/mds.20288
32.
EvansAHKatzenschlagerRPaviourDO'SullivanJDAppelSLawrenceADet al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord. (2004) 19:397–405. 10.1002/mds.20045
33.
CorvolJCArtaudFCormier-DequaireFRascolODurifFDerkinderenPet al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. (2018) 91:e189–201. 10.1212/WNL.0000000000005816
34.
KesslerRCChiuWTDemlerOWaltersEE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. (2005) 62:617–27. 10.1001/archpsyc.62.6.617
35.
De MiccoRRussoATedeschiGTessitoreA. Impulse control behaviors in Parkinson's disease: drugs or disease? Contribution from imaging studies. Front Neurol. (2018) 9:893. 10.3389/fneur.2018.00893
36.
SmithKMXieSKDaniel WeintraubD. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry. (2016) 87:864–70. 10.1136/jnnp-2015-311827
37.
Driver-DunckleyESamantaJStacyM. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology. (2003) 61:422–3. 10.1212/01.WNL.0000076478.45005.EC
38.
MaiaAFPintoASBarbosaERMenezesPRMiguelEC. Obsessive-compulsive symptoms, obsessive-compulsive disorder, and related disorders in Parkinson's disease. J Neuropsychiatry Clin Neurosci. (2003) 15:371–4. 10.1176/jnp.15.3.371
39.
SarathchandranPSomanSSarmaGKrishnanSKishoreA. Impulse control disorders and related behaviors in Indian patients with Parkinson's disease. Mov Disord. (2013) 28:1901–2. 10.1002/mds.25557
40.
Rodríguez-ViolanteMGonzález-LatapiPCervantes-ArriagaACamacho-OrdoñezAWeintraubD. Impulse control and related disorders in Mexican Parkinson's disease patients. Parkinsonism Relat Disord. (2014) 20:907–10. 10.1016/j.parkreldis
41.
RizosASauerbierAAntoniniAWeintraubDMartinez-MartinPKesselBet al. European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. (2016) 23:1255–61. 10.1111/ene.13034
42.
BiundoRWeisLAbbruzzeseGCalandra-BuonauraGCortelliPJoriMCet al. Impulse control disorders in advanced Parkinson's disease with dyskinesia: the ALTHEA Study. Mov Disord. (2017) 32:1557–65. 10.1002/mds.27181
43.
WeintraubDHoopsSSheaJALyonsKEPahwaRDriver-DunckleyEDet al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. (2009) 24:1461–7. 10.1002/mds.22571
44.
WeintraubDMamikonyanEPapayKSheaJAXieSXSiderowfA. Questionnaire for impulsive-compulsive disorders in Parkinson's disease-rating scale. Mov Disord. (2012) 27:242–7. 10.1002/mds.24023
45.
Martinez-MartinPRodriguez-BlazquezCCatalanMJEDISStudyGroup. Independent and complementary validation of the QUIP-RS in advanced Parkinson's disease. Mov Disord Clin Pract. (2018) 5:341–2. 10.1002/mdc3.12603
46.
ProbstCCWinterLMMöllerBWeberHWeintraubDWittKet al. Erratum to: validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. J Neurol. (2015) 262:2200. 10.1007/s00415-015-7882-5
47.
ChristensonGAFaberRJMitchellJE. Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry. (1994) 55:5–11.
48.
GrantJEChamberlainSROdlaugBL. Clinical Guide to Obsessive Compulsive and Related Disorders. New York, NY: Oxford University Press (2014).
49.
ChamberlainSRGrantJE. Minnesota Impulse Disorders Interview (MIDI): Validation of a structured diagnostic clinical interview for impulse control disorders in an enriched community sample. Psychiatry Res. (2018) 265:279–83. 10.1016/j.psychres.2018.05.006
50.
CabriniSBarattiMBonfaFCabriGUberEAvanziN. Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive–compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease. Neurol Sci. (2009) 30:307–13. 10.1007/s10072-009-0101-3
51.
GoetzCGTilleyBCShaftmanSRStebbinsGTFahnSMartinez-MartinPet al. Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. (2008) 23:2129–70. 10.1002/mds.22340
52.
PattonJHStanfordMSBarrattES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. (1995) 51:768–74. 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1
53.
Martínez-LoredoVFernández-HermidaJRFernández-ArtamendiSCarballoJLGarcía-RodríguezO. Spanish adaptation and validation of the Barratt Impulsiveness Scale for early adolescents (BIS-11-A). Int J Clin Health Psychol. (2015) 15:274–82. 10.1016/j.ijchp.2015.07.002
54.
EllouzeFGhaffariOZouariOZouariBM'radMF. Validation of the dialectal Arabic version of Barratt's impulsivity scale, the BIS-11. Encephale. (2013) 39:13–8. 10.1016/j.encep.2012.06.034
55.
von DiemenLSzobotCMKesslerFPechanskyF. Adaptation and construct validation of the Barratt Impulsiveness Scale (BIS 11) to Brazilian Portuguese for use in adolescents. Braz J Psychiatry. (2007) 29:153–6. 10.1590/S1516-44462006005000020
56.
RieuIMartinez-MartinPPereiraBDe ChazeronIVerhagen MetmanLJahanshahiMet al. International validation of a behavioral scale in Parkinson's disease without dementia. Mov Disord. (2015) 30:705–13. 10.1002/mds.26223
57.
du ToitPLvan KradenburgJNiehausDSteinDJ. Comparison of obsessive-compulsive disorder patients with and without comorbid putative obsessive-compulsive spectrum disorders using a structured clinical interview. Compr Psychiatry. (2001) 4:291–300. 10.1053/comp.2001.24586
58.
OkaiDAskey-JonesSMackJMartinAChaudhuriKRSamuelMet al. Parkinson's impulse-control scale for the severity rating of impulse-control behaviors in Parkinson's Disease: a semistructured clinical assessment tool. Mov Disord Clin Pract. (2016) 3:494–9. 10.1002/mdc3.12316
59.
JoutsaJMartikainenKVahlbergTVoonVKaasinenV. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord. (2012) 18:155–60. 10.1016/j.parkreldis.2011.09.007
60.
VoonVNapierTCFrankMJSgambato-FaureVGraceAARodriguez-OrozMet al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. Lancet Neurol. (2017) 16:238–50. 10.1016/S1474-4422(17)30004-2
61.
LeeJYJeonBKohSBYoonWTLeeHWKwonODet al. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. J Neurol Neurosurg Psychiatry. (2018) 0:1–8. 10.1136/jnnp-2018-318942
62.
CallesenaMBScheel-KrugerbJKringelbachMLMølleraA. A systematic review of impulse control disorders in Parkinson's disease. J Parkinsons Dis. (2013) 3:105–38. 10.3233/JPD-120165
63.
RossiMBrunoVArenaJCammarotaÁMerelloM. Challenges in PD patient management after DBS: a pragmatic review. Mov Disord Clin Pract. (2018) 5:246–54. 10.1002/mdc3.12592
64.
HouetoJLMagnardRDalleyJWBelinDCarnicellaS. Trait impulsivity and anhedonia: two gateways for the development of impulse control disorders in Parkinson's disease?Front Psychiatry. (2016) 7:91. 10.3389/fpsyt.2016.00091
65.
CiliaRvan EimerenT. Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain Struct Funct. (2011) 216:289–99. 10.1007/s00429-011-0314-0
66.
VriendCPattijTvan der WerfYDVoornPBooijJRuttenSet al. Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?Neurosci Biobehav Rev. (2014) 38:60–71. 10.1016/j.neubiorev.2013.11.001
67.
SiriCCiliaRRealiEPozziBCeredaEColomboAet al. Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders. Mov Disord. (2015) 30:696–704. 10.1002/mds.26160
68.
VitaleCSantangeloGTrojanoLVerdeFRoccoMGrossiDet al. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease. Mov Disord. (2011) 26:830–6. 10.1002/mds.23567
69.
SiriCCiliaRDe GaspariDCanesiMMeucciNZecchinelliALet al. Cognitive status of patients with Parkinson's disease and pathological gambling. J Neurol. (2010) 257:247–52. 10.1007/s00415-009-5301-5
70.
Cormier-DequaireFBekadarSAnheimMLebbahSPelissoloAKrackPet al. Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. Mov Disord. (2018) 33:1878–86. 10.1002/mds.27519
71.
Zainal AbidinSTanELChanSCJaafarALeeAXAbd HamidMHet al. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients. BMC Neurol. (2015) 15:59. 10.1186/s12883-015-0316-2
72.
ErgaAHDalenIUshakovaAChungJTzoulisCTysnesOet al. Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson's disease. Front Neurol. (2018) 9:109. 10.3389/fneur.2018.00109
73.
KrishnamoorthySRajanRBanerjeeMKumarHSarmaGKrishnanSet al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. Parkinsonism Relat Disord. (2016) 30:13–7. 10.1016/j.parkreldis.2016.06.005
74.
CardinalRNParkinsonJAHallJEverittBJ. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci Biobehav Rev. (2002) 26:321–52. 10.1016/S0149-7634(02)00007-6
75.
BrewerJPotenzaM. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol. (2008) 75:63–75. 10.1016/j.bcp.2007.06.043
76.
van OostenRVVerheijMMCoolsAR. Bilateral nigral 6-hydroxydo-pamine lesions increase the amount of extracellular dopamine in the nucleus accumbens. Exp Neurol. (2005) 191:24–32. 10.1016/j.expneurol.2004.09.004
77.
BuckholtzJWTreadwayMTCowanRLWoodwardNDLiRAnsariMSet al. Dopaminergic network differences in human impulsivity. Science. (2010) 329:532. 10.1126/science.1185778
78.
DalleyJWFryerTDBrichardLRobinsonESTheobaldDELaaneKet al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine rein-forcement. Science. (2007) 315:1267–70. 10.1126/science.1137073
79.
ClaassenDvan den WildenbergWRidderinkhofKJessupCHarrisonMWootenGet al. The risky business of dopamine agonists in Parkinson's disease and impulse control disorders. Behav Neurosci. (2011) 125:492–500. 10.1037/a0023795
80.
KeelerJFPretsellDORobbinsTW. Functional implications of dopamine D1 vs. D2 receptors: a ‘prepare and select’ model of the striatal direct vs. indirect pathways. Neuroscience. (2014) 282:156–75. 10.1016/j.neuroscience.2014.07.021
81.
RamdaveSDawsonACarterADissanayakaNNW. Unmasking neurobiological commonalities between addictive disorders and impulse control disorders in Parkinson's disease. Brain Imaging Behav. (2019) 1:e00041–7. 10.1007/s11682-019-00041-7
82.
MeyerGMSpayCLaurencinCBallangerBSescousseGBoulinguezP. Functional imaging studies of impulse control disorders in Parkinson's disease need a stronger neurocognitive footing. Neurosci Biobehav Rev. (2019) 98:164–76. 10.1016/j.neubiorev.2019.01.008
83.
BiundoRFormento-DojotPFacchiniSVallelungaAGhezzoLFoscoloLet al. Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci. (2011) 310:64–9. 10.1016/j.jns.2011.08.001
84.
BiundoRWeisLFacchiniSFormento-DojotPVallelungaAPilleriMet al. Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. Mov Disord. (2015) 30:688–95. 10.1002/mds.26154
85.
CerasaASalsoneMNigroSChiriacoCDonzusoGBoscoDet al. Cortical volume and folding abnormalities in Parkinson's disease patients with pathological gambling. Parkinsonism Relat Disord. (2014) 20:1209–14. 10.1016/j.parkreldis.2014.09.001
86.
ImperialeFAgostaFCanuEMarkovicVInuggiAJecmenica-LukicMet al. Brain structural and functional signatures of impulsive-compulsive behaviours in Parkinson's disease. Mol Psychiatry. (2018) 23:459–66. 10.1038/mp.2017.18
87.
MarkovicVAgostaFCanuEInuggiAPetrovicIStankovicIet al. Role of habenula and amygdala dysfunction in Parkinson disease patients with punding. Neurology. (2017) 88:2207–15. 10.1212/WNL.0000000000004012
88.
PellicanoCNiccoliniFWuKO'SullivanSSLawrenceADLeesAJet al. Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. J Neurol. (2015) 262:2653–61. 10.1007/s00415-015-7892-3
89.
RicciardiLLambertCDe MiccoRMorganteFEdwardsM. Can we predict development of impulsive-compulsive behaviours in Parkinson's disease?J Neurol Neurosurg Psychiatry. (2018) 89:476–81. 10.1136/jnnp-2017-317007
90.
RuitenbergMFLWuTAverbeckBBChouKLKoppelmansVSeidlerRD. Impulsivity in Parkinson's disease is associated with alterations in affective and sensorimotor striatal networks. Front Neurol. (2018) 9:279. 10.3389/fneur.2018.00279
91.
TessitoreASantangeloGDe MiccoRVitaleCGiordanoARaimoSet al. Cortical thickness changes in patients with Parkinson's disease and impulse control disorders. Parkinsonism Relat Disord. (2016) 24:119–25. 10.1016/j.parkreldis.2015.10.013
92.
YooHBLeeJYLeeJSKangHKimYKSongICet al. Whole-brain diffusion-tensor changes in parkinsonian patients with impulse control disorders. J Clin Neurol. (2015) 11:42–7. 10.3988/jcn.2015.11.1.42
93.
CanuEAgostaFMarkovicVPetrovicIStankovicIImperialeFet al. White matter tract alterations in Parkinson's disease patients with punding. Parkinsonism Relat Disord. (2017) 43:85–91. 10.1016/j.parkreldis.2017.07.025
94.
Mojtahed ZadehMAshraf-GanjoueiAGhazi SherbafFHaghshomarMAarabiMH. White matter tract alterations in drug-naïve Parkinson's disease patients with impulse control disorders. Front Neurol. (2018) 9:163. 10.3389/fneur.2018.00163
95.
CarriereNLopesRDefebvreLDelmaireCDujardinK. Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease. Neurology. (2015) 84:1–8. 10.1212/WNL.0000000000001619
96.
TessitoreADe MiccoRGiordanoAdi NardoFCaiazzoGSicilianoMet al. Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease. Mov Disord. (2017) 32:1710–9. 10.1002/mds.27139
97.
TessitoreASantangeloGDe MiccoRGiordanoARaimoSAmboniMet al. Resting-state brain networks in patients with Parkinson's disease and impulse control disorders. Cortex. (2017) 94:63–72. 10.1016/j.cortex.2017.06.008
98.
ClaassenDOStarkAJSpearsCAPetersenKvan WouweNKesslerRet al. Mesocorticolimbic hemodynamic response in Parkinson' s diseases patients with compulsive behaviors. Mov Disord. (2017) 32:1574–83. 10.1002/mds.27047
99.
LoaneCWuKO'SullivanSSLawrenceADWoodheadZLeesAJet al. Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism Relat Disord. (2015) 21:1336–41. 10.1016/j.parkreldis.2015.09.042
100.
PetersenKVan WouweNStarkALinYCKangHTrujillo-DiazPet al. Ventral striatal network connectivity reflects reward learning and behavior in patients with Parkinson's disease. Hum Brain Mapp. (2018) 39:509–21. 10.1002/hbm.23860
101.
PolitisMLoaneCWuKO'SullivanSSWoodheadZKiferleLet al. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain. (2013) 136:400–11. 10.1093/brain/aws326
102.
RaoHMamikonyanEDetreJASiderowfADSternMBPotenzaMNet al. Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov Disord. (2010) 25:1660–9. 10.1002/mds.23147
103.
VoonVPessiglioneMBrezingCGalleaCFernandezHHDolanRJet al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron. (2010) 65:135. 10.1016/j.neuron.2009.12.027
104.
VoonVGaoJBrezingCSymmondsMEkanayakeVFernandezHet al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain. (2011) 134:1438–46. 10.1093/brain/awr080
105.
EvansAHPaveseNLawrenceADTaiYFAppelSDoderMet al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. (2006) 59:852–8. 10.1002/ana.20822
106.
O'SullivanSSWuKPolitisMLawrenceADEvansAHBoseSKet al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain. (2011) 134:969–78. 10.1093/brain/awr003
107.
SteevesTDLMiyasakiJZurowskiMLangAEPellecchiaGvan EimerenTet al. Increased striatal dopamine release in parkinsonian patients with pathological gambling: A 11C raclopride PET study. Brain. (2009) 132:1376–85. 10.1093/brain/awp054
108.
WuKPolitisMO'SullivanSSLawrenceADWarsiSBoseSet al. Single versus multiple impulse control disorders in Parkinson's disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine reléase. J Neurol. (2015) 262:1504–14. 10.1007/s00415-015-7722-7
109.
PayerDEGuttmanMKishSJTongJStrafellaAZackMet al. [11C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders. Mov Disord. (2015) 30:160–6. 10.1002/mds.26135
110.
RayNJMiyasakiJMZurowskiMKoJHChoSSPellecchiaGet al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis. (2012) 48:519–25. 10.1016/j.nbd.2012.06.021
111.
JoutsaJMartikainenKNiemeläSJohanssonJForsbackSRinneJOet al. Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord. (2012) 27:778–82. 10.1002/mds.24941
112.
van EimerenTPellecchiaGCiliaRBallangerBSteevesTDHouleSet al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology. (2010) 75:1711–6. 10.1212/WNL.0b013e3181fc27fa
113.
LeeJYSeoSHKimYKYooHBKimYESongICet al. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. J Neurol Neurosurg Psychiatry. (2014) 85:23–30. 10.1136/jnnp-2013-305549
114.
VergerAKlesseEChawkiMBWitjasTAzulayJPEusebioAet al. Brain PET substrate of impulse control disorders in Parkinson's disease: A metabolic connectivity study. Hum Brain Mapp. (2018) 39:3178–86. 10.1002/hbm.24068
115.
CiliaRSiriCMarottaGIsaiasIUDe GaspariDCanesiMet al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol. (2008) 65:1604–11. 10.1001/archneur.65.12.1604
116.
CiliaRKoJHChoSSvan EimerenTMarottaGPellecchiaGet al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis. (2010) 39:98–104. 10.1016/j.nbd.2010.03.013
117.
VoonVRizosAChakravarttyRMulhollandNRobinsonSHowellNAet al. Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry. (2014) 85:148–52. 10.1136/jnnp-2013-305395
118.
VriendCNordbeckAHBooijJvan der WerfYDPattijTVoornPet al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. Mov Disord. (2014) 29:904–11. 10.1002/mds.25886
119.
PremiEPilottoAGaribottoVBigniBTurroneRAlbericiAet al. Impulse control disorder in PD: a lateralized monoaminergic frontostriatal disconnection syndrome?Parkinsonism Relat Disord. (2016) 30:62–6. 10.1016/j.parkreldis.2016.05.028
120.
van EimerenTBallangerBPellecchiaGMiyasakiJMLangAEStrafellaAP. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?Neuropsychopharmacoly. (2009) 34:2758–66. 10.1038/sj.npp.npp2009124
121.
StarkAJSmithCTLinYCPetersenKJTrujilloPvan WouweNCet al. Nigrostriatal and mesolimbic D(2/3) receptor expression in parkinson's disease patients with compulsive reward-driven behaviors. J Neurosci. (2018) 38:3230–9. 10.1523/JNEUROSCI.3082-17.2018
122.
RyanSAO'SullivanSS. Impulsive-compulsive behaviours in Parkinson's disease–prevention is better than cure. Ir Med J. (2013) 106:162.
123.
Ramirez-ZamoraAGeeLBoydJBillerJ. Treatment of impulse control disorders in Parkinson's disease: practical considerations and future directions. Expert Rev Neurother. (2016) 16:389–99. 10.1586/14737175.2016.1158103
124.
BrockPFisherJMHandAWalkerRW. Highlighting the goals for Parkinson's care: commentary on NICE guidelines for Parkinson's in adults (NG71). Age Ageing. (2018). [Epub ahead of print]. 10.1093/ageing/afy158
125.
KimAKimYEKimHJYunJYYangHJLeeWWet al. A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease. Parkinsonism Relat Disord. (2018) 56:3–8. 10.1016/j.parkreldis.2018.07.010
Summary
Keywords
impulse control disorders, ICD, pathological gambling, binge eating, hypersexual disorder, compulsive buying, Parkinson disease
Citation
Gatto EM and Aldinio V (2019) Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review. Front. Neurol. 10:351. doi: 10.3389/fneur.2019.00351
Received
02 August 2018
Accepted
22 March 2019
Published
17 April 2019
Volume
10 - 2019
Edited by
Angelo Antonini, University of Padova, Italy
Reviewed by
Giovanna Calandra-Buonaura, University of Bologna, Italy; Eleonora Fiorenzato, IRCCS Fondazione Ospedale San Camillo, Italy
Updates
Copyright
© 2019 Gatto and Aldinio.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Emilia M. Gatto emiliamgatto@gmail.com
This article was submitted to Movement Disorders, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.